FOLH1 and prostate carcinoma: Specifically, it focuses on PET tracers like radiolabelled Prostate‐Specific Membrane Antigen (PSMA) and their integration into biopsy‐guided diagnosis, supporting personalised management for prostate cancer patients while adapting the best choice to each patient's clinical situation.